Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches

John H. Strickler, Christina Wu, Tanios Bekaii-Saab

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

Original languageEnglish (US)
Pages (from-to)109-119
Number of pages11
JournalCancer Treatment Reviews
Volume60
DOIs
StatePublished - Nov 1 2017

    Fingerprint

Keywords

  • BRAF
  • Colorectal cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this